Tetrahydrobiopterin as a novel therapeutic intervention for autism

Neurotherapeutics

Volumn 7, Issue 3, 2010, Pages 241-249

  Frye, Richard E ^a   Huffman, Lynne C ^b,c   Elliott, Glen R ^b,c,d  

^a UNIVERSITY OF TEXAS   (United States)

^b Children's Health Council   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Autism spectrum disorder; Monoamine neurotransmitters; Nitric oxide; Tetrahydrobiopterin; Treatment

Indexed keywords

6 PYRUVOYLTETRAHYDROPTERIN SYNTHASE; IBUPROFEN; KUVAN; PLACEBO; SAPROPTERIN; TETRAHYDROBIOPTERIN; UNCLASSIFIED DRUG; AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; BIOPTERIN; NITRIC OXIDE;

ABDOMINAL PAIN; AGGRESSION; ARTICLE; AUTISM; BIOSYNTHESIS; CEREBROSPINAL FLUID LEVEL; DIARRHEA; DRUG CEREBROSPINAL FLUID LEVEL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ENURESIS; EXCITEMENT; GASTROESOPHAGEAL REFLUX; GROUPS BY AGE; HEADACHE; HUMAN; HYPERKINESIA; INTELLIGENCE QUOTIENT; IRRITABILITY; NAUSEA; NONHUMAN; PANIC; PHENYLKETONURIA; POLYURIA; PRIORITY JOURNAL; PTERIN DEFICIENCY; SALIVATION; SIDE EFFECT; SLEEP DISORDER; SYNCOPE; TIC; TREATMENT DURATION; TREATMENT RESPONSE; URINARY FREQUENCY; URINE LEVEL; VOMITING; ANALOGS AND DERIVATIVES; AUTISTIC DISORDER; METABOLISM;

AUTISTIC DISORDER; BIOPTERIN; HUMANS; NEUROTRANSMITTER AGENTS; NITRIC OXIDE;

EID: 77954946690     PISSN: 19337213     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nurt.2010.05.004     Document Type: Article

References (51)

1. Rogers S.J., Ozonoff S. Behavioral, educational, and developmental treatments of autism. Understanding autism: from basic neuroscience to treatment 2006, 443-473. CRC Taylor & Francis, Boca Raton, FL. S.O. Moldin, J.L.R. Rubenstein (Eds.).
2. Buitelaar J. Why have drug treatments been so disappointing?. Autism: neural basis and treatment possibilities 2003, 235-249. Novartis Foundation, New York. G. Bock, J. Goode (Eds.).
3. McDougle C.J., Posey D.J., Stigler K.A. Pharmacological Treatments. Understanding autism: from basic neuroscience to treatment 2006, 417-442. CRC Taylor & Francis, Boca Raton, FL. S.O. Moldin, J.L.R. Rubenstein (Eds.).
4. Vitiello B., Wagner A. Government initiatives in autism clinical trials. CNS Spectr 2004, 9:66-73.
5. ThÖny B., Auerbach G., Blau N. Tetrahydrobiopterin biosynthesis, regeneration and functions. Biochem J 2000, 347(Pt 1):1-16.
6. Hyland K., Surtees R.A., Heales S.J., Bowron A., Howells D.W., Smith I. Cerebrospinal fluid concentrations of pterins and metabolites of serotonin and dopamine in a pediatric reference population. Pediatr Res 1993, 34:10-14.
7. Tani Y., Fernell E., Watanabe Y., Kanai T., LångstrÖm B. Decrease in 6R-5,6,7,8-tetrahydrobiopterin content in cerebrospinal fluid of autistic patients. Neurosci Lett 1994, 181:169-172.
8. Dietert R.R., Dietert J.M. Potential for early-life immune insult including developmental immunotoxicity in autism and autism spectrum disorders: focus on critical windows of immune vulnerability. J Toxicol Environ Health B Crit Rev 2008, 11:660-680.
9. Castellani M.L., Conti C.M., Kempuraj D.J., et al. Autism and immunity: revisited study. Int J Immunopathol Pharmacol 2009, 22:15-19.
10. Pardo C.A., Vargas D.L., Zimmerman A.W. Immunity, neuroglia and neuroinflammation in autism. Int Rev Psychiatry 2005, 17:485-495.
11. James S.J., Cutler P., Melnyk S., et al. Metabolic biomarkers of increased oxidative stress and impaired methylation capacity in children with autism. Am J Clin Nutr 2004, 80:1611-1617.
12. Deth R., Muratore C., Benzecry J., Power-Charnitsky V.A., Waly M. How environmental and genetic factors combine to cause autism: a redox/methylation hypothesis. Neurotoxicology 2008, 29:190-201.
13. Pardo C.A., Eberhart C.G. The neurobiology of autism. Brain Pathol 2007, 17:434-447.
14. Kern J.K., Jones A.M. Evidence of toxicity, oxidative stress, and neuronal insult in autism. J Toxicol Environ Health B Crit Rev 2006, 9:485-499.
15. Koshimura K., Murakami Y., Tanaka J., Kato Y. Self-protection of PC12 cells by 6R-tetrahydrobiopterin from nitric oxide toxicity. J Neurosci Res 1998, 54:664-672.
16. Kojima S., Ona S., Iizuka I., Arai T., Mori H., Kubota K. Antioxidative activity of 5,6,7,8-tetrahydrobiopterin and its inhibitory effect on paraquat-induced cell toxicity in cultured rat hepatocytes. Free Radic Res 1995, 23:419-430.
17. McDougle C.J., Kresch L.E., Goodman W.K., et al. A case-controlled study of repetitive thoughts and behavior in adults with autistic disorder and obsessive-compulsive disorder. Am J Psychiatry 1995, 152:772-777.
18. Kolevzon A., Mathewson K.A., Hollander E. Selective serotonin reuptake inhibitors in autism: a review of efficacy and tolerability. J Clin Psychiatry 2006, 67:407-414.
19. Posey D.J., Erickson C.A., Stigler K.A., McDougle C.J. The use of selective serotonin reuptake inhibitors in autism and related disorders. J Child Adolesc Psychopharmacol 2006, 16:181-186.
20. Soorya L., Kiarashi J., Hollander E. Psychopharmacologic interventions for repetitive behaviors in autism spectrum disorders. Child Adolesc Psychiatr Clin N Am 2008, 17:753-771. viii.
21. Mulder E.J., Anderson G.M., Kema I.P., et al. Platelet serotonin levels in pervasive developmental disorders and mental retardation: diagnostic group differences, within-group distribution, and behavioral correlates. J Am Acad Child Adolesc Psychiatry 2004, 43:491-499.
22. Bramham J., Ambery F., Young S., et al. Executive functioning differences between adults with attention deficit hyperactivity disorder and autistic spectrum disorder in initiation, planning and strategy formation. Autism 2009, 13:245-264.
23. Corbett B.A., Constantine L.J., Hendren R., Rocke D., Ozonoff S. Examining executive functioning in children with autism spectrum disorder, attention deficit hyperactivity disorder and typical development. Psychiatry Res 2009, 166:210-222.
24. Jahromi L.B., Kasari C.L., McCracken J.T., et al. Positive effects of methylphenidate on social communication and self-regulation in children with pervasive developmental disorders and hyperactivity. J Autism Dev Disord 2009, 39:395-404.
25. Troost P.W., Steenhuis M.P., Tuynman-Qua H.G., et al. Atomoxetine for attention-deficit/hyperactivity disorder symptoms in children with pervasive developmental disorders: a pilot study. J Child Adolesc Psychopharmacol 2006, 16:611-619.
26. Posey D.J., Wiegand R.E., Wilkerson J., Maynard M., Stigler K.A., McDougle C.J. Open-label atomoxetine for attention-deficit/hyperactivity disorder symptoms associated with high-functioning pervasive developmental disorders. J Child Adolesc Psychopharmacol 2006, 16:599-610.
27. Nakane Y., Naruse H., Hayashi T., Takesada M., Yamazaki K. Clinical effect of R-THBP on Infantile Autism. Neurobiology of infantile autism: Proceedings of the International Symposium on Neurobiology of Infantile Autism, Tokyo, 10-11 November 1990 1992, 337-349. Elsevier Science Publishers, New York. H. Naruse, E. Ornitz (Eds.).
28. Naruse H., Hayashi T., Takesada M. A preliminary study on clinical effect of tetrahydrobiopterin in infantile autism [In Japanese]. Reports in 1983 for New Drug Development 1984, 71-81. Ministry of Health and Welfare, Tokyo.
29. Naruse H., Hayashi T., Takesada M., Nakane Y., Yamazaki K. Metabolic changes in aromatic amino acids and monoamines in infantile autism and development of new treatment related to the findings [In Japanese]. No to Hattatu 1989, 21:181-189.
30. Naruse H., Hayashi T., Takesada M., et al. Therapeutic effect of tetrahydrobiopterin in infantile autism. Proc Jpn Acad 1987, 63B:231-233.
31. Naruse H., Takesada M., Nakane Y., et al. Clinical evaluation of R-tetrahydrobiopterin (SUN 0588) on infantile autism: a double-blind comparative study using placebo as a control [Japanese]. Rinsho Iyaku 1990, 6:1343-1368.
32. Naruse H., Takesada M., Nagahata M., Kazamatsuri H., Nakane Y., Yamazaki K. An open clinical study of sapropterin hydrochloride (R-tetrahydrobiopterin SUN 0588) in infantile autism: clinical study using a Rating Scale for Abnormal Behaviors in Children [Japanese]. Rinsho Iyaku 1990, 6:1859-1875.
33. Nagahata M., Kazamatsuri H., Naruse H., et al. Clinical evaluation of sapropterin hydrochloride (R-THBP. SUN 0588) on infantile autism: a multicenter cooperative study [Japanese]. Rinsho Iyaku 1990, 6:1877-1899.
34. Nakane Y., Asuo T., Shimogawa S., Fujiwara T., Kawabata Y., Kubota J. Clinical efficacy and effects on physical development of long-term treatment of R-tetrahydrobiopterin (R-THBP, SUN 0588) for autism[Japanese]. Kiso to Rinsho 1990, 24:4579-4598.
35. Takesada M., Naruse H., Nagahata M. An open clinical study of sapropterin hydrochloride (R-tetrahydrobiopterin, R-THBP) in infantile autism: clinical effects and long-term follow-up. Neurobiology of infantile autism: Proceedings of the International Symposium on Neurobiology of Infantile Autism, Tokyo, 10-11 November 1990 1992, 355-358. Elsevier Science Publishers, New York. H. Naruse, E. Ornitz (Eds.).
36. Danfors T., von Knorring A.L., Hartvig P., et al. Tetrahydrobiopterin in the treatment of children with autistic disorder: a double-blind placebo-controlled crossover study. J Clin Psychopharmacol 2005, 25:485-489.
37. Fernell E., Watanabe Y., Adolfsson I., et al. Possible effects of tetrahydrobiopterin treatment in six children with autism-clinical and positron emission tomography data: a pilot study. Dev Med Child Neurol 1997, 39:313-318.
38. Miller L., Insel T., Scheinin M., et al. Tetrahydrobiopterin administration to rhesus macaques: its appearance in CSF and effect on neurotransmitter synthesis. Neurochem Res 1986, 11:291-298.
39. Kapatos G., Kaufman S. Peripherally administered reduced pterins do enter the brain. Science 1981, 212:955-956.
40. Brand M.P., Hyland K., Engle T., Smith I., Heales S.J. Neurochemical effects following peripheral administration of tetrahydropterin derivatives to the hph-1 mouse. J Neurochem 1996, 66:1150-1156.
41. Canevari L., Land J.M., Clark J.B., Heales S.J. Stimulation of the brain NO/cyclic GMP pathway by peripheral administration of tetrahydrobiopterin in the hph-1 mouse. J Neurochem 1999, 73:2563-2568.
42. ThÖny B., Calvo A.C., Scherer T., et al. Tetrahydrobiopterin shows chaperone activity for tyrosine hydroxylase. J Neurochem 2008, 106:672-681.
43. Kaufman S., Kapatos G., McInnes R.R., Schulman J.D., Rizzo W.B. Use of tetrahydropterins in the treatment of hyperphenylalaninemia due to defective synthesis of tetrahydrobiopterin: evidence that peripherally administered tetrahydropterins enter the brain. Pediatrics 1982, 70:376-380.
44. Ferraris S., Guardamagna O., Bonetti G., et al. Fate of peripherally administered tetrahydrobiopterin in congenital tetrahydrobiopterin deficiency. Unconjugated pterins and related biogenic amines: proceedings of the first international workshop, Flims, Switzerland, February 28-March 7, 1987 1987, 283-292. Walter de Gruyter, New York. H.C. Curtius, N. Blau, R.A. Levine (Eds.).
45. al Aqeel A., Ozand P.T., Gascon G.G., Hughes H., Reynolds C.T., Subramanyam S.B. Response of 6-pyruvoyl-tetrahydropterin synthase deficiency to tetrahydrobiopterin. J Child Neurol 1992, 7(Suppl):S26-S30.
46. Investigator's brochure. Version 4.0 2008, BioMarin Pharmaceutical Inc., BioMarin Pharmaceutical, Novato, CA.
47. Tegenge M.A., Bicker G. Nitric oxide and cyclic GMP signal transduction positively regulates the motility of human neuronal precursor (NT2) cells. J Neurochem 2009, 110:1828-1841.
48. Garthwaite J. Concepts of neural nitric oxide-mediated transmission. Eur J Neurosci 2008, 27:2783-2802.
49. Anastasiadis P.Z., Bezin L., Imerman B.A., Kuhn D.M., Louie M.C., Levine R.A. Tetrahydrobiopterin as a mediator of PC12 cell proliferation induced by EGF and NGF. Eur J Neurosci 1997, 9:1831-1837.
50. Koshimura K., Miwa S., Lee K., Fujiwara M., Watanabe Y. Enhancement of dopamine release in vivo from the rat striatum by dialytic perfusion of 6R-l-erythro-5,6,7,8-tetrahydrobiopterin. J Neurochem 1990, 54:1391-1397.
51. Mataga N., Imamura K., Watanabe Y. l-Threo-3,4-dihydroxyphenylserine enhanced ocular dominance plasticity in adult cats. Neurosci Lett 1992, 142:115-118.